SR 4554
Alternative Names: SR4554Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Cancer Research Technology; SRI International
- Class Antineoplastics; Imaging agents; Nitroimidazoles; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Diagnosis) in United Kingdom (IV, Infusion)
- 19 Nov 2007 SR 4554 is available for licensing (http://www.sri.com)
- 04 May 2005 Data presented at the 96th Annual Meeting of the American Association for Cancer Research (AACR-2005) have been added to the adverse events and pharmacokinetics sections